Wedbush Upgrades Meridian Biosciences (VIVO) to Neutral

July 26, 2013 8:29 AM

Wedbush upgraded Meridian Biosciences (NASDAQ: VIVO) from Underperform to Neutral with a price target of $21.00 (from $17.00). Analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found